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What Is the Evidence Linking Changes in the
Microbiota to the Development of Allergic
Disease?
Two lines of evidence suggest that environmental changes are a
major factor in the development of allergies: the increase in the
incidence of allergic diseases over the past 20–30 years and the
dichotomy in the rate of allergic disease between industrialized
and developing countries. These observations have led researchers
to propose the ‘‘hygiene hypothesis’’ for allergies and asthma.
Simply stated, a lack of early microbial stimulation results in
aberrant immune responses to innocuous antigens later in life [1].
However, an alternative interpretation of the evidence supporting
the hygiene hypothesis forms the foundation of the ‘‘microbiota
(microflora) hypothesis’’ [2,3]. The concept is that significant
perturbations in gastrointestinal (GI) microbiota composition in
westernized areas (due to antibiotic use, dietary changes, and other
lifestyle differences) have disrupted the mechanisms of mucosal
immunologic tolerance. Epidemiologic and clinical data support-
ing this interpretation include 1) a positive correlation between
increasing risk for asthma/allergies and increasing use antibiotics
in industrialized countries, 2) correlations between altered fecal
microbiota composition and atopic disease, and 3) successful
prevention/reduction of allergies in some individuals by oral
probiotics or dietary changes. Experimental data in mice include
the observations that 1) germ-free animals display numerous
defects in immune response generation, 2) antibiotic treatment can
augment Th2 type immune responses, and 3) probiotics can
diminish airway allergic responses. Altogether, these experimental,
epidemiologic, and clinical observations support the hypothesis
that changes in the indigenous microbiota can be a predisposing
factor for allergic disease.
How Stable Is the Microbiota and Can It Be
Altered?
The mucosal surfaces in the body are the home to the
indigenous microbiota that, in humans, is estimated to be
composed of 10–100 trillion microbes, with a diversity of greater
than 1,000 species [4,5]. The highest concentration of microbes is
found in the GI tract, while extremely low numbers are found in
the airways. Healthy human lungs are not sterile [6], as previously
believed [7–8], but it is unknown whether the microbes in the
lungs form a stable community or are a series of transient
colonizers.
Throughout the rest of the mucosa, the microbiota at each site
resides as a stable climax community, which is defined as a
microbial community that has reached a final or ‘‘climax’’ steady
state as a result of a series of ecological successions that have
selected species best adapted for growth at that specific niche along
the mucosa. However, this climax community is dynamic and still
exhibits both resistance and resilience [9,10], i.e., it has the ability
to maintain a given community structure in the face of
perturbation, but is also able to return to its baseline structure
following environmental perturbation after resistance is broken.
Evidence is now accumulating that long-term dietary pressures
and repeated antibiotic use can break both the resistance and
resilience of a community and result in it re-assembling into
another climax community [11,12], although this may be
accompanied by detrimental changes in host mucosal immunobi-
ology and physiology. Other environmental pressures on the
indigenous microbiota can include GI illnesses or medications
such as antacids, proton pump inhibitors, and non-steroidal anti-
inflammatory drugs. One mechanism underlying the activity of
probiotic microbes and prebiotic nutrients may be the ability to
restructure a climax community to improve host mucosal
immunobiology and physiology.
How Are Microbiota Changes and Mucosal
Immune Responses in the Gut Linked to Mucosal
Immunity in the Lungs?
The mucociliary architecture of the nasopharyngeal cavity and
upper airways naturally sweeps all inhaled micro-particulates that
stick to the mucus lining into the GI tract. Shortly after intranasal
inoculation, fluids, particles, and microbes introduced into the
nasal cavity are largely found in the GI tract [2]. Thus, inhaled
micro-particulates (which comprise the vast majority of aeroaller-
gens) are also swallowed. For example, in one animal model of
allergic airway disease, two days after intranasal administration of
antigenic peptide, corresponding Ag-specific CD4 T cell division
had not only occurred in the lymph nodes draining the lungs and
nasopharyngeal cavity, but also in the mesenteric lymph nodes
[13]. No division was seen in peripheral non-draining nodes.
The propensity of ingested antigens to block subsequent
systemic immune responses is termed oral tolerance [14]. It is
likely that oral tolerance and airway tolerance are tightly linked
and the GI tract acts as a ‘‘sensor’’ for the development of
tolerance to inhaled and injected antigens. The results of
depletion, reconstitution, and adoptive transfer studies have
demonstrated that tolerance to low amounts of ingested allergens
is mediated by CD4+ regulatory T cells (Tregs). The mechanisms
of Treg-mediated suppression are not entirely known, but it is
clear that Tregs require T cell receptor stimulation and that
production of immunosuppressive cytokines, IL-10 and TGFb, are
critical mediators in vivo [15]. Thus, Tregs require specific
activation but can mediate nonspecific suppression in what is
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cells and T cells are also central to mucosal tolerance and mucosal
signals, such as those from the microbiota, that keep resident
dendritic cells in an immature or non-inflammatory state will
promote the development of Tregs. This could be true for all
mucosal sites. Our hypothesis is that this ‘‘sensor’’ system for
mucosal tolerances can be modified by genetics (affecting innate
immune cells) and to an even greater extent by perturbations of
microbiota signaling exerted by antibiotics and significant dietary
changes. While generation of Tregs is one mechanism, there are
likely a number of others that may involve humoral immunity,
innate mechanisms, and potentially even neurogenic pathways
[16]. It remains to be determined how these distal mucosal sites
interact in generating mucosal immunity and what the microbial
signals are that promote tolerance, although they are likely to
include short chain fatty acids and zwitterionic polysaccharides
[17,18].
What Is the Role of Indigenous Yeast in This
Cross-Kingdom Signaling in the Mucosa?
Candida albicans and other Candida species are a normal part of
the human microbiota and reside in low numbers in the mouth,
vagina, and GI tract of healthy individuals. The composition of the
microbiota, hormones, stress, innate immunity, and adaptive
immunity are all factors that impact the levels of Candida
colonization. Increased levels of Candida species in the microbiota
have been implicated for decades in a number of hypersensitivity
diseases, although a definitive mechanistic understanding has been
lacking [19]. C. albicans colonization of the GI mucosa has been
implicated at some level in 1) atopic dermatitis, a chronic
inflammatory skin disease; 2) celiac disease, an allergic/autoim-
mune reaction to gluten; 3) Crohn’s disease, an inflammatory
bowel disease in which anti–Saccharomyces cerevisiae antibodies
(ASCA) develop that are reactive to a cell wall epitope of C.
albicans that is expressed in vivo but not in standard culture; and 4)
‘‘fungal-type dysbiosis’’ (reported in the popular media as ‘‘yeast
syndrome’’), a controversial diagnosis defined as multiple mani-
festations of a diverse collection of syndromes, including food
sensitivities, allergic responses, digestive problems, and psycho-
neurological manifestations.
We have demonstrated that colonization of mice by C. albicans
following broad-spectrum antibiotic therapy (cefoperazone) can
promote the development of allergic airway disease [20,21]. These
responses were maximal in mice that received both antibiotic
treatment and oral introduction of C. albicans, implicating a need
for a change in both the bacterial and fungal microbiota to
promote the development of allergic disease. Other studies have
demonstrated that extraluminal leak of antigen is greater in C.
albicans–colonized mice than in C. albicans–free mice [22]. The
mechanisms underlying these observations are still under investi-
gation, but Candida species (and many other fungi) can secrete
prostaglandins and prostaglandin-like molecules de novo or via
conversion of exogenous arachidonic acid [23]. Prostaglandins are
potent immunomodulatory molecules that can promote Th2 type
responses and tissue eosinophilia. Fungal cell wall glucans are also
powerful inflammatory stimulants in tissues and may also play a
role in the immunomodulatory activity of yeast in the GI tract.
Finally, there is antagonism between Candida and members of the
indigenous microbiota, which may impact bacterial–host immu-
noregulatory responses in the mucosa.
Can the Microbiota Be Targeted for Therapy of
Allergic Disease and, If So, How?
The composition of the microbiota can be manipulated by
combinations of antibiotics, probiotics, and dietary components.
Probiotics are defined as live microbes that, when delivered in
sufficient quantities, exert a beneficial effect on health [24,25].
Probiotic consumption has been practiced for over a century and
has resulted in a large body of anecdotal evidence that suggests a
connection to improved health. Fortunately, these are being
replaced by clinical studies and mechanistic investigations that are
demonstrating positive results for probiotics, both therapeutically
and preventatively. Many dietary components also have direct
growth promoting or inhibiting activity for specific microbes, such
as certain types of fatty acids, phenolic compounds, and
carbohydrates. However, a single type of probiotic or dietary
component will not be efficacious in all individuals. This likely
owes to differences in the types of microbial communities in
different individuals. The objective of the international Human
Microbiome Project is to characterize and define the human
microbiome in states of health and disease [26]. The challenge for
future research is to use this information to optimize probiotic/
dietary therapy to improve human health and prevent microbiota-
associated diseases, such as allergies.
References
1. Wills-Karp M, Santeliz J, Karp CL (2001) The germless theory of allergic
disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1: 69–75.
2. Noverr MC, Huffnagle GB (2005) The ‘microflora hypothesis’ of allergic
diseases. Clin Exp Allergy 35: 1511–1520.
3. Blaser MJ (2006) Who are we? Indigenous microbes and the ecology of human
diseases. EMBO Rep 7: 956–960.
4. Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces
shaping microbial diversity in the human intestine. Cell 124: 837–848.
5. O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep
7: 688–693.
6. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, et al. (2010) Disordered
microbial communities in asthmatic airways. PLoS ONE 5: e8578. doi:10.1371/
journal.pone.0008578.
7. Kahn FW, Jones JM (1987) Diagnosing bacterial respiratory infection by
bronchoalveolar lavage. J Infect Dis 155: 862–869.
8. Thorpe JE, Baughman RP, Frame PT, Wesseler TA, Staneck JL (1987)
Bronchoalveolar lavage for diagnosing acute bacterial pneumonia. J Infect Dis
155: 855–861.
9. Allison SD, Martiny JB (2008) Colloquium paper: resistance, resilience, and
redundancy in microbial communities. Proc Natl Acad Sci U S A 105 Suppl 1:
11512–11519.
10. Little AE, Robinson CJ, Peterson SB, Raffa KF, Handelsman J (2008) Rules of
engagement: interspecies interactions that regulate microbial communities.
Annu Rev Microbiol 62: 375–401.
11. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, et al.
(2009) Reproducible Community Dynamics of the Gastrointestinal Microbiota
Following Antibiotic Perturbation. Infect Immun.
12. Dethlefsen L, Huse S, Sogin ML, Relman DA (2008) The pervasive effects of an
antibiotic on the human gut microbiota, as revealed by deep 16S rRNA
sequencing. PLoS Biol 6: e280. doi:10.1371/journal.pbio.0060280.
13. Lambrecht BN, Pauwels RA, Fazekas De St Groth B (2000) Induction of rapid T
cell activation, division, and recirculation by intratracheal injection of dendritic
cells in a TCR transgenic model. J Immunol 164: 2937–2946.
14. Mowat AM (2003) Anatomical basis of tolerance and immunity to intestinal
antigens. Nat Rev Immunol 3: 331–341.
15. Belkaid Y (2007) Regulatory T cells and infection: a dangerous necessity. Nat
Rev Immunol 7: 875–888.
16. Meggs WJ (1995) Neurogenic switching: a hypothesis for a mechanism for
shifting the site of inflammation in allergy and chemical sensitivity. Environ
Health Perspect 103: 54–56.
17. Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor
prevents intestinal inflammatory disease. Nature 453: 620–625.
18. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ (2006) Colonic health:
fermentation and short chain fatty acids. J Clin Gastroenterol 40: 235–243.
19. Goldman DL, Huffnagle GB (2009) Potential contribution of fungal infection
and colonization to the development of allergy. Med Mycol 22: 1–12.
20. Noverr MC, Falkowski NR, McDonald RA, McKenzie AN, Huffnagle GB
(2005) Development of allergic airway disease in mice following antibiotic
PLoS Pathogens | www.plospathogens.org 2 May 2010 | Volume 6 | Issue 5 | e1000549therapy and fungal microbiota increase: role of host genetics, antigen, and
interleukin-13. Infect Immun 73: 30–38.
21. Noverr MC, Noggle RM, Toews GB, Huffnagle GB (2004) Role of antibiotics
and fungal microbiota in driving pulmonary allergic responses. Infect Immun 72:
4996–5003.
22. Yamaguchi N, Sugita R, Miki A, Takemura N, Kawabata J, et al. (2006)
Gastrointestinal Candida colonisation promotes sensitisation against food
antigens by affecting the mucosal barrier in mice. Gut 55: 954–960.
23. Noverr MC, Erb-Downward JR, Huffnagle GB (2003) Production of eicosanoids
and other oxylipins by pathogenic eukaryotic microbes. Clin Microbiol Rev 16:
517–533.
24. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME (2009) Probiotics
and immunity. J Gastroenterol 44: 26–46.
25. Douglas LC, Sanders ME (2008) Probiotics and prebiotics in dietetics practice.
J Am Diet Assoc 108: 510–521.
26. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, et al. (2007)
The human microbiome project. Nature 449: 804–810.
PLoS Pathogens | www.plospathogens.org 3 May 2010 | Volume 6 | Issue 5 | e1000549